Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder

Summary

This is a 5-year double blind, randomized, controlled, trial conducted at three treatment sites, aimed at showing the acute and longer-term effects of DCS augmentation of exposure-based CBT for panic disorder relative to placebo augmentation. By demonstrating that DCS can enhance the results of even a brief treatment strategy, the investigators are seeking to validate an approach that fits well with the practice limitations and applications of CBT in effectiveness studies.

Timeline

Start

2008-04

Primary completion

2014-08

Completion

2014-08

Outcome

Met primary endpoint

paper DCS augmentation resulted in significant benefit only early in the trial, with no beneficial effects of DCS augmentation evident at follow-up evaluations. PMID 27315514 ↗

paper reflected an acceleration of treatment response evident at treatment endpoint, but no advantage in response over follow-up evaluation. PMID 27315514 ↗

Publications

• Results Otto MW, Pollack MH, Dowd SM, Hofmann SG, Pearlson G, Szuhany KL, Gueorguieva R, Krystal JH, Simon NM, Tolin DF. RANDOMIZED TRIAL OF D-CYCLOSERINE ENHANCEMENT OF COGNITIVE-BEHAVIORAL THERAPY FOR PANIC DISORDER. Depress Anxiety. 2016 Aug;33(8):737-45. doi: 10.1002/da.22531. Epub 2016 Jun 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cycloserine	Small molecule	50 mg	—

Indications